Key result
Phase 3 cardiac rehabilitation cost-effectively prolongs survival by ~1.8 years.
Why the study?
Does Phase 3 cardiac rehabilitation improve survival in patients with ischemic heart disease?
Does Phase 3 cardiac rehabilitation improve survival in patients with ischemic heart disease?
Phase 3 cardiac rehabilitation is a cost-effective intervention that prolongs survival in patients with ischemic heart disease.
Answers are grounded in this paper and cite their sources.
Supports Phase 3 cardiac rehabilitation as cost-effective; leaves open need for prospective randomized confirmation.
The third phase of the Cardiac Rehabilitation Program (CRP) is a lifelong, maintenance phase beginning 3 to 6 months after the cardiac event. Individualized surveillance and monitoring schedules are established. The exercise prescription guidelines are practically identical to those of the other phases of the CRP with personalized monitoring. Currently, with the emergence of the COVID-19 pandemic, telerehabilitation and telemonitoring are of great value in this phase. The benefits of phase 3 have been demonstrated with prolonged survival by 1.82 years, at a cost of $ 1773 per year of life saved.
No takes yet. Share an insight, caveat, or question.
Ignacio de la Torre (2021) conducted a review in Ischemic heart disease. Phase 3 Cardiac Rehabilitation Program was evaluated on Survival and cost-effectiveness (Prolonged survival by 1.82 years). Phase 3 cardiac rehabilitation prolongs survival by 1.82 years at a cost of $1773 per year of life saved.
Synapse has enriched 10 related papers. Consider them for comparative context: